Pereyra, G. | Search bioRxiv

bioRxiv2025

SFRP1 drives glycolytic activation in astrocytes during neuroinflammation

Astrocytes and microglia maintain brain homeostasis and respond to inflammation through functions coordinated by molecular mediators they produce. Growing evidence shows that cellular metabolism is key to how these cells adapt to challenges. However, little is known about what drives glial metabolic reprogramming or whether molecules involved in astrocyte- microglia crosstalk also regulate this process. Here, we explored this question focusing on Secreted Frizzled-Related Protein 1 (SFRP1). SFRP1 is an astrocyte-derived factor induced by inflammatory cues and overexpressed in neurodegeneration, which fosters microglial response to inflammation through NF-{kappa}B/HIF-dependent programs. We combined mitochondrial morphometry (MitoTracker Red and MiNA analysis) with Seahorse extracellular flux assays (Mito Stress Test) to determine whether SFRP1 modulates glial bioenergetics in primary cultures of astrocytes and microglia from wild-type and Sfrp1-/- mice. We report that SFRP1 acts as a driver of astrocytic metabolic activation, preferentially enhancing glycolysis over mitochondrial respiration. This effect is most pronounced during inflammation, when oxidative phosphorylation is restricted and SFRP1 enhances glycolytic flexibility to sustain energy demands. By contrast, microglia showed the expected LPS-driven glycolytic shift with minimal dependence on SFRP1 under monoculture conditions. These findings position SFRP1 as a candidate regulator of astrocyte-centered metabolic tuning during neuroinflammation, with implications for disorders such as Alzheimers disease, in which SFRP1 is elevated.

neuroscience↗

bioRxiv2024

SFRP1 upregulation causes hippocampal synaptic dysfunction and memory impairment

Decreased dendritic complexity and impaired synaptic function are strongly linked to cognitive decline in Alzheimers disease (AD), and precede the emergence of other neuropathological traits that establish a harmful cycle exacerbating synaptic dysfunction. SFRP1, a glial-derived protein regulating cell-cell communication, is abnormally elevated in the brain of AD patients and related mouse models already at early disease stages. Neutralization of SFRP1 activity in mice reduces the occurrence of protein aggregates, neuroinflammation and prevents the loss of synaptic long-term potentiation (LTP). In this study, we generated transgenic mice that overexpress Sfrp1 in astrocytes to investigate whether LTP loss is due to an early influence of SFRP1 on synaptic function or results from other alterations driving disease progression. We report that SFRP1-overexpressing mice show reduced dendritic complexity and spine density in dentate gyrus granule cells during early adulthood, prior to a significant deficit in LTP response and late onset cognitive impairment. Ultrastructural analysis revealed the loss of small-sized synapses and presynaptic alterations in transgenic mice. Analysis of proteomic changes points to a general decrease in protein synthesis and modifications in the synaptic proteome, particularly of proteins related to synaptic vesicle cycle and synaptic organizers, like neurexin and neuroligin. We propose a model wherein SFRP1 directly impacts on synaptic function, by increasing the availability of synaptic organizing molecules at the synapse. These observations, combined with documented SFRP1 effects on APP processing and microglial activation, imply that SFRP1 contributes to multiple pathological effects in AD, emerging as a promising therapeutic target for this devastating disease.

neuroscience↗